Hyperion DeFi Inc

Aktienanalyse zu Hyperion DeFi Inc (HYPD)

$2.510

-0.049 (-1.95%)Zum Schluss

Loading chart…
Hoch
2.671
Eröffnung
2.600
Volumengewichteter Durchschnittskurs
2.51
Volumen
427.17K
Marktkap.
—
Tief
2.360
Umsatz
1.07M
EV/EBITDA, TTM
-0.88

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.

hyperiondefi.com

KI-Analyse of Hyperion DeFi Inc (HYPD)

Kaufen

Hyperion DeFi Inc is a good buy right now due to its recent positive developments and strong growth potential. The stock is currently priced at $3.29, significantly below its 52-week high of $6.48, indicating a potential for recovery. Additionally, the company has raised its 2026 adjusted gross profit guidance from $5 million to a new range of $7 million to $8 million, showcasing its improving financial outlook. However, investors should be cautious of the high volatility, as the stock has experienced a 49.83% decline over the past year, which poses a risk.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Hyperion DeFi Inc (HYPD) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -0.57.

Erwartetes KGV

Stark überbewertet
5J-Durchschnitt P/E
-0.57
Aktuelles P/E
0.00
Überbewertet
-0.41
Unterbewertet
-0.73

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-0.82
Aktuelles EV/EBITDA
-0.88
Überbewertet
-0.30
Unterbewertet
-1.35

Erwartetes KUV

Unterbewertet
5J-Durchschnitt P/S
13.87
Aktuelles P/S
6.77
Überbewertet
18.67
Unterbewertet
9.06

Event-Zeitleiste

2026-10-02 (ET)

10:00:00

Coinbase Receives CFTC Approval for Derivatives Clearing

08:30:00

Hyperion DeFi Repurchases 240,124 HYPD Shares and Retires $8.6M Debt

2026-09-28 (ET)

09:30:00

Hyperion DeFi Named Launch Partner for Frontier's Hyperliquid Vault

2026-09-11 (ET)

10:00:00

Nasdaq to Invest $100M in Payward

2026-09-08 (ET)

09:00:00

Hyperion DeFi Launches $20M Share Buyback Program

News

HYPD FAQ – beantwortet von Alphio AI

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles. It operates in the Healthcare sector.

Hyperion DeFi Inc is a good buy right now due to its recent positive developments and strong growth potential. The stock is currently priced at $3.29, significantly below its 52-week high of $6.48, indicating a potential for recovery. Additionally, the company has raised its 2026 adjusted gross profit guidance from $5 million to a new range of $7 million to $8 million, showcasing its improving financial outlook. However, investors should be cautious of the high volatility, as the stock has experienced a 49.83% decline over the past year, which poses a risk.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln